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INTRODUCTION
It has been demonstrated that when total renal mass is
reduced in chronic renal failure (CRF), single nephron glome-
rular filtration rate (SNGFR) in the remaining nephrons
markedly increases, thereby leading to an increased reabsorp-
tive burden on the residual nephrons (1). This together with
the compensatory renal hypertrophy is associated with sig-
nificant alterations in tubular reabsorptive capacities of sodi-
um and water. In CRF, there is an adaptive increase in sodi-
um excretion by each residually functioning nephron (2, 3).
In this way, sodium balance can be maintained despite a di-
minishing GFR when intake of salt and water is unaltered
in CRF. The mechanisms responsible for the increased frac-
tional sodium excretion and marked natriuresis per nephron
in remnant kidney have previously been investigated (3-5).
In particular, we have previously performed a profiling study
in rats with CRF (6, 7), demonstrating that densities per
nephron of type 3 Na/H exchanger (NHE3), type-2 Na-Pi
cotransporter (NaPi-2), and Na-K-ATPase (alpha1-subunit)
do not increase proportionately to the extensive nephron hy-
pertrophy, associated with the hyperfiltration in remnant
nephrons. In contrast, the densities per nephron of both rat
type 1 bumetanide-sensitive Na-K-2Cl cotransporter (BSC-1)
in the thick ascending limb (TAL) and thiazide-sensitive Na-
Cl cotransporter (TSC) in the distal convoluted tubule (DCT)
were significantly increased. Also, there was no decrease in Na-
K-ATPase immunolabeling in TAL and DCT. Thus, the ex-
pression of sodium transporters in the TAL and DCT was not
decreased in remnant kidneys, indicating that the altered tubu-
lar handling of sodium in CRF may be caused primarily by
the changes in expression levels of proximal tubule sodium
transporters and that there appears to be a compensatory in-
crease in sodium transporter expression in the distal nephron.
It has been demonstrated that renin-angiotensin-aldosterone
(RAA) system is activated in CRF and the key role of AngII
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Angiotensin II AT1 Receptor Blockade Changes Expression of Renal
Sodium Transporters in Rats with Chronic Renal Failure 
We aimed to examine the effects of angiotensin II AT1 receptor blocker on the expres-
sion of major renal sodium transporters and aquaporin-2 (AQP2) in rats with chronic
renal failure (CRF). During 2 wks after 5/6 nephrectomy or sham operation, both
CRF rats (n=10) and sham-operated control rats (n=7) received a fixed amount of
low sodium diet and had free access to water. CRF rats (n=10) were divided into
two groups which were either candesartan-treated (CRF-C, n=4) or vehicle-treated
(CRF-V, n=6). Both CRF-C and CRF-V demonstrated azotemia, decreased GFR,
polyuria, and decreased urine osmolality compared with sham-operated rats. When
compared with CRF-V, CRF-C was associated with significantly higher BUN levels
and lower remnant kidney weight. Semiquantitative immunoblotting demonstrated
decreased AQP2 expression in both CRF-C (54% of control levels) and CRF-V (57%),
whereas BSC-1 expression was increased in both CRF groups. Particularly, CRF-C
was associated with higher BSC-1 expression (611%) compared with CRF-V (289%).
In contrast, the expression of NHE3 (25%) and TSC (27%) was decreased in CRF-C,
whereas no changes were observed in CRF-V. In conclusion, 1) candesartan treat-
ment in an early phase of CRF is associated with decreased renal hypertrophy and
increased BUN level; 2) decreased AQP2 level in CRF is likely to play a role in the
decreased urine concentration, and the downregulation is not altered in response to
candesartan treatment; 3) candesartan treatment decreases NHE3 and TSC expres-
sion; and 4) an increase of BSC-1 is prominent in candesartan-treated CRF rats,
which could be associated with the increased delivery of sodium and water to the
thick ascending limb.
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in the progression of CRF has been revealed in several studies
(8, 9). We have previously demonstrated that chronic infu-
sion of supraphysiological doses of AngII in normal rats was
associated with significantly increased abundance and apical
expression level of the Na-H exchanger NHE3 and Na-K-
2Cl cotransporter BSC-1 in medullary thick ascending limbs
(mTAL), whereas Na,K-ATPase and electroneutral Na-HCO3
cotransporter (NBCn1) levels remained unchanged (10). In
the proximal tubule of AngII-treated rats, the overall abun-
dance of NHE3 and Na,K-ATPase remained unchanged. In
contrast immunoperoxidase microscopy and confocal laser
scanning microscopy demonstrated that NHE3 immunola-
beling in the brush border of the proximal tubules was mar-
kedly enhanced in AngII-treated rats, suggesting that high
plasma AngII levels may contribute to an enhanced renal Na+
and HCO3- reabsorption in kidney tubules by increasing the
abundance of NHE3 and BSC-1 in mTAL cells as well as
increasing NHE3 expression in the proximal tubule brush
border. Therefore, the activated RAA system in parallel to
the changes of SNGFR and renal hypertrophy in CRF could
be involved in the changes of renal sodium handling and of
the expression of renal sodium transporters.
Two main subtypes of the Ang II receptor, AT1 and AT2,
have been characterized. Most of the physiological and patho-
physiological actions of AngII are mediated by the AT1 recep-
tor, and AT1 receptors can be blocked by specific AT1 recep-
tor antagonists. Compared to ACE inhibitors, AT1 receptor
antagonists inhibit the RAA system more specifically block-
ing the effects of AngII at the receptor level without interfer-
ing with the bradykinin metabolism. In the present study, we
aimed to examine the effects of AngII AT1 receptor blockade
on the expression of major renal sodium transporters (NHE3,
BSC-1, and TSC) and vasopressin-regulated aquaporin-2
(AQP2) in rats with an early stage of CRF induced by 5/6
nephrectomy. This would be an extension of our previous
studies (6, 7, 10, 11) and could further elucidate the role of
AngII on the expression of renal sodium transporters in the
kidney tubule segments.
MATERIALS AND METHODS
Experimental animals
The studies were performed on adult male Sprague-Dawley
rats initially weighing 200-210 g (Hyochang Science, Daegu,
Korea). The rats were maintained on a standard rodent diet
with free access to water before the experiments. 
Induction of chronic renal failure by surgical reduction of
renal mass
Experimental CRF was induced by excision of about 2/3 of
the right kidney and left total nephrectomy, using the so-called
excision remnant kidney model (6, 7). The protocols used in
this study are depicted in Fig. 1. The rats were anesthetized
with isoflurane (Choongwae Pharma Corporation, Seoul, Korea)
and during the surgery the rats were placed on a heated table
to maintain rectal temperature at 37-38℃. The right kidney
was exposed through right flank incision, gently dissected
free from the adrenal gland, and approximately two-thirds of
the right kidney including the upper and lower pole was ex-
cised. One week later, these rats were again anesthetized with
isoflurane, the left kidney was removed through left flank inci-
sion after dissecting it free from the adrenal gland. The wound
was closed with 4/0 silk and metal clamps. Immediately after
each surgical procedure, rats were allowed to recover from anes-
thesia and surgery in individual cages. As a control group, rats
were subjected to sham operation identical to the ones used
for CRF rats except that kidneys or poles of kidney were not
removed. Sham-operated rats were monitored for two weeks
in parallel with 5/6 nephrectomized rats (Fig. 1). All rats were
killed under isoflurane anesthesia and kidneys were rapidly
removed and processed for protein preparation at the same day.
We have chosen 2 week-follow-up after induction of 5/6 ne-
phrectomy to 1) produce chronic renal insufficiency, 2) to allow
significant hypertrophy of the remnant kidney, and 3) to min-
imize interstitial fibrosis, as previously demonstrated (6, 7).
Experimental protocol
During the 2 weeks after 5/6 nephrectomy and sham oper-
CRF-V
(n=6)
-9 -7 0 7 14 (days)
** ** ** **
CRF-C
(n=4)
-9 -7 0 7 14 (days)
** ** ** **
Sham
(n=7)
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Nephrectomy 
or Sham op
Left total
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or Sham op
Sacrifice
Low sodium diet
(0.13 mEqNa/220 g bw/day)
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** ** ** **
Fig. 1. A diagram of the study design. CRF was induced in rats
by right 2/3 nephrectomy followed by contralateral nephrectomy
(n=10). Sham-operated control rats matching CRF rats (n=7). Both
CRF rats and sham-operated control rats received a fixed amount
of low sodium diet for 2 wks after induction of CRF. Two groups
of CRF are made: CRF rats treated with vehicle (CRF-V, n=6) and
CRF rats treated with candesartan (CRF-C, n=4). Sham-operated
control rats were also treated with vehicle. The rats were maintained
in metabolic cages at the days marked with asterisk (*), allowing
monitoring of daily urine output and water intake. The stippled lines
indicated the treatment of vehicle or candesartan in each group. 250 E.-J. Kim, Y.-W. Jung, T.-H. Kwon
ation, all CRF rats and sham-operated rats received a fixed
amount (15 g/220 g bw/day) of low sodium diet (TD 90228,
Harlan Teklad, Madison, WI, which the supplier indicated
0.02% Na+) to supply same amount of sodium intake and
to increase endogenous angiotensin II and aldosterone levels
in both CRF rats and sham-operated control rats, as previously
demonstrated (12, 13). CRF rats (n=10) were divided into
two groups which were either vehicle-treated (CRF-V, n=6)
or candesartan-treated (CRF-C, 1 mg/kg/day for 2 wks, s.c.,
n=4). The estimated daily sodium intake in food per rat was
0.13 mEq Na+/220 g bw/day*. They had free access to water
intake. For candesartan infusion to CRF rats, osmotic mini-
pumps (Model 2002, Alzet Co, Palo Alto, CA, U.S.A.) were
implanted subcutaneously in the neck of each rat (6). For
implantation, osmotic minipumps were filled with candesar-
tan (AT1 receptor blocker, a gift from the AstraZeneca Phar-
maceutical, Sweden) dissolved in 0.02M Na2CO3 in physio-
logic saline (14). The pumps were equilibrated with physio-
logic saline at 37℃ for 4 hr before insertion. The dose of can-
desartan (when given in drinking water) has been shown to
be sufficient to block the rise in blood pressure resulting from
long-term infusion of angiotensin II (15). 
Clearance studies
The rats were maintained in the metabolic cages during
the specific days indicated as asterisks in Fig. 1, allowing
quantitative urine collections and measurements of water
intake. Urine volume, osmolality, and urine creatinine con-
centration were measured. Blood was collected from the ab-
dominal aorta at the time of sacrifice for measurement of
serum sodium and potassium concentration, creatinine, and
osmolality. Urine sodium measurement could not be obtained
since the concentration was at a very low level to detect in
an automatic analyzer.
Membrane fractionation and immunoblotting
All rats were killed under light isoflurane anesthesia and
right kidneys were rapidly removed and were homogenized
(Ultra-Turrax T8 homogenizer, IKA Labortechnik, Staufen,
Germany) in ice-cold isolation solution containing 0.3 M
sucrose, 25 mM imidazole, 1 mM EDTA, 8.5  M leupeptin,
1 mM phenylmethylsulfonyl fluoride, pH 7.2. To remove
whole cells, nuclei and mitochondria, the homogenates were
centrifuged at 4,000 g for 15 min at 4℃and the supernatant
was pipetted off and kept on ice for further processing. The
total protein concentration was measured (Pierce BCA pro-
tein assay reagent kit, Pierce, Rockford, IL, U.S.A.) and all
samples were adjusted with isolation solution to reach the
identical final protein concentrations (for this study, we adjust-
ed the final protein concentration of each kidney from CRF
rats and sham-operated control rats to 10  g/ L) and solu-
bilized at 65℃ for 15 min in Laemmli sample buffer, and
then stored at -20℃. To confirm equal loading of protein,
an initial gel was stained with Coomassie blue dye, as des-
cribed previously (10). SDS-PAGE was performed on 9% or
12% polyacrylamide gels. The proteins were transferred from
the gel electrophoretically (BioRad Mini Protean II) to nitro-
cellulose membranes (Hybond ECL RPN3032D, Amersham
Pharmacia Biotech, Little Chalfont, U.K.). After transfer
the blots were blocked with 5% milk in PBS-T (80 mM
Na2HPO4, 20 mM Na2HPO4, 100 mM NaCl, 0.1% Tween
20, pH 7.5) for 1 hr and incubated overnight at 4℃ with
primary antibodies. Immunoblotting was performed using
anti-rat AQP2 (7), anti-rat NHE3 (6, 10), anti-rat BSC-1
(6, 10), and anti-rat TSC antibodies (6, 10). The sites of
antibody-antigen reaction were visualized with horseradish
peroxidase (HRP)-conjugated secondary antibodies (P448,
diluted 1: 3,000; DAKO, Glostrup, Denmark) with an en-
hanced chemiluminescence (ECL) system and exposure to
photographic film (Hyperfilm ECL, RPN3103K, Amersham
Pharmacia Biotech, Little Chalfont, U.K.). The band densi-
ties were quantitated by scanning the films and the density
was calculated as a fraction of the mean control value for
that gel.
Statistical analyses
Values were presented as means±standard errors. Data
were analyzed by one-way analysis of variance (ANOVA)
followed by Bonferroni’s multiple comparisons test. Multi-
ple comparisons tests were only applied when a significant
difference was determined in the ANOVA, p<0.05. 
RESULTS
Rats with CRF, both vehicle-treated (CRF-V) and cande-
sartan-treated (CRF-C), showed increased urine output
and decreased urine osmolality compared with sham-oper-
ated control rats 
Urine output was significantly increased after induction
of 5/6 nephrectomy in CRF rats (both CRF-V and CRF-C),
whereas there was no change in urine output after sham oper-
ation in control rats (Fig. 2, Table 1). The urine output was
similar between CRF-V and CRF-C (Fig. 2, Table 1), indi-
cating that the high urine output seen in rats with CRF was
not affected by the candesartan treatment. Consistent with
the increased urine output in CRF, the urine osmolality was
significantly decreased in both CRF-V and CRF-C, compared
with sham-operated rats (Table 1).
*Sample calculation: 1) daily food intake in each rat: 15 g/220 g bw; 2)
Na
+ content in food (Harlan Teklad, TD 90228): 0.02%; 3) daily Na
+ intake
in rat: (15 g/220 g bw)×0.02%=0.003 g Na
+/220 g bw/day; 4) 1 mmoL
Na
+=23 mg; 5) thus 0.003 gNa
+/220 g bw/day corresponds to 0.13 mmoL
Na
+/220 g bw/day (0.13 mEq Na
+/220 g bw/day).Ang II AT1 Receptor Blockade in CRF 251
CRF rats treated with candesartan (CRF-C) had higher
levels of blood urea nitrogen and lower kidney weight com-
pared with CRF rats treated with vehicle (CRF-V)
BUN levels were significantly increased in CRF rats (both
CRF-V and CRF-C) compared with sham-operated rats, res-
pectively (Table 1). This indicated that they had a significant
azotemia (Table 1). Moreover, BUN level in CRF rats treat-
ed with candesartan was much higher than that of CRF rats
treated with vehicle (153.8±9.6 in CRF-C vs. 77.2±13.9
mg/dL in CRF-V, p<0.05, Table 1). Consistent with the sig-
nificant azotemia, serum creatinine level was increased and
creatinine clearance was decreased in CRF rats with no dif-
ference between the two CRF groups (CRF-V vs. CRF-C,
Table 1). CRF rats treated with vehicle was associated with
significant hypertrophy of remnant renal mass, evidenced by
the increase of kidney weight comparable to the correspond-
ing right kidney weight of sham-operated control rats despite
2/3 nephrectomy of right kidney (0.39±0.02 in CRF-V vs.
0.36±0.004 g/100 g bw in sham-operated control rats, not
significant (n.s.), Table 1). In contrast, candesartan treatment
in CRF rats (CRF-C) was associated with significantly decreased
kidney weight compared with vehicle-treated CRF rats (0.29
±0.03 vs. 0.39±0.02 g/100 g bw, p<0.05, Table 1), sug-
gesting that candesartan treatment in an early phase of CRF
significantly reduced the renal hypertrophy and AngII could
play a role in this process.
Kidney expression of AQP2 was decreased in CRF rats,
both vehicle-treated (CRF-V) and candesartan-treated
(CRF-C)
Semi-quantitative immunoblotting of whole kidney pro-
tein samples from CRF rats (remnant kidney) and sham-oper-
ated rats (corresponding right whole kidney) demonstrated
that CRF rats, both vehicle-treated (57±9% of sham-oper-
ated control level, p<0.05) and candesartan-treated (54±6%
CRF-V CRF-C Sham
No. of rats 6 4 7
Body Weight (g) 270±11* 229±11*
,� 321±4
Urine output (mL/d) 33.3±2.7* 36.3±4.4* 13.4±1.2
U-Osm (mosm/KgH2O) 563±45* 479±25* 1,576±193
BUN (mg/dL) 77.2±13.9* 153.8±9.6*
,� 22.5±1.2
Cr (mg/dL) 1.05±0.11* 1.48±0.19* 0.47±0.02
s-Na (mEq/L) 139.5±0.8 139.3±0.9 140.7±0.3
s-K (mEq/L) 6.0±0.4 6.5±0.5 5.3±0.1
Ccr (mL/min/100 g bw) 0.21±0.03* 0.14±0.02* 0.48±0.03
Kidney weight 0.39±0.02 0.29±0.03*
,� 0.36±0.004
(g/100 g bw)
Table 1. Changes in renal function
Kidney weight was measured with the remnant kidney in rats with CRF
or with the corresponding right kidney in sham-operated control rats.
*p<0.05 when CRF-V or CRF-C was compared with sham-operated con-
trols; 
� p<0.05 when CRF-C was compared with CRF-V.
CRF-V CRF-C Sham
No. of rats 6 4 7
AQP2 57±9* 54±6* 100±15
BSC-1 289±63* 611±126*
,� 100±30
NHE3 76±16 25±5*
,� 100±4
TSC 75±16 27±13*
,� 100±16
Table 2. Densitometric analysis of immunoblots from rats with
CRF and sham-operated controls
*p<0.05 when CRF-V or CRF-C was compared with sham-operated con-
trols; 
� p<0.05 when CRF-C was compared with CRF-V.
Fig. 2. Time course of the changes in urine output in CRF rats
and sham-operated rats. Urine output was significantly increased
after induction of 5/6 nephrectomy in CRF rats (both CRF-V (cir-
cle) and CRF-C (rectangle)), whereas there is no change in urine
output after sham operation in control rats (triangle). *p<0.05
when CRF-V or CRF-C was compared with sham-operated con-
trol rats.
Fig. 3. Decreased expression of AQP2 in CRF-V and CRF-C.
Immunoblot of whole  kidney protein samples from CRF rats and
sham-operated control rats. (A) The immunoblot was reacted
with affinity purified anti-AQP2 and reveals 29 kDa and 35-50
kDa AQP2 bands, representing non-glycosylated and glycosy-
lated forms of AQP2. (B) Densitometric analysis demonstrated
a decrease in AQP2 expression in CRF-V and CRF-C, compared
with sham-operated control rats (Sham). *p<0.05 when CRF-V
or CRF-C was compared with sham-operated control rats.
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of sham-operated control level, p<0.05), had significantly
decreased AQP2 expression compared with sham-operated
controls (Fig. 3, Table 2). In contrast, the whole kidney AQP2
expression in CRF rats was not altered in response to candesar-
tan treatment (Fig. 3, Table 2).
Kidney expression of BSC-1 was increased in CRF rats
both vehicle-treated (CRF-V) and candesartan-treated
(CRF-C)
Semi-quantitative immunoblotting of whole kidney pro-
tein samples from CRF rats and sham-operated rats demon-
strated that CRF rats, both vehicle-treated and candesartan-
treated, had significantly increased BSC-1 expression, com-
pared with sham-operated controls (Fig. 4, Table 2). More-
over, candesartan treatment in CRF rats significantly increased
whole kidney BSC-1 expression (611±126% of sham-oper-
ated control level), compared with CRF rats treated with vehi-
cle only (289±63% of sham-operated control level, p<0.05,
Fig. 4, Table 2).
Kidney expression of NHE3 and TSC was decreased in
CRF rats treated with candesartan (CRF-C) 
Candesartan treatment significantly decreased whole kid-
ney NHE3 expression in CRF rats (25±5% of sham-oper-
ated control level, p<0.05, Fig. 5, Table 2), whereas whole
kidney NHE3 expression was unchanged in CRF rats treated
with vehicle only (76±16% of sham-operated control level,
n.s., Fig. 5, Table 2). Moreover, densitometric analysis revealed
that candesartan treatment significantly decreased whole kid-
ney TSC expression in CRF rats (27±13% of sham-operat-
ed control level, p<0.05, Fig. 6, Table 2), whereas whole kid-
ney TSC expression was unchanged in CRF rats treated with
vehicle only (75±16% of sham-operated control level, n.s.,
Fig. 6, Table 2). 
Fig. 4. Increased expression of BSC-1 in CRF-V and CRF-C. Im-
munoblot of whole kidney protein samples from CRF and sham-
operated control rats. (A) The immunoblot was reacted with affin-
ity purified anti-BSC-1 and recognized a broad band of molec-
ular mass 146-176 kDa. (B) Densitometric analysis revealed a
significant increase of BSC-1 expression in CRF-V and CRF-C
compared with sham-operated rats (Sham). Moreover, CRF-C
was associated with higher BSC-1 expression compared with
CRF-V. *p<0.05 when CRF-V or CRF-C was compared with sham-
operated controls, 
� p<0.05 when CRF-C was compared with
CRF-V.
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Fig. 5. Decreased expression of NHE3 in CRF-C. Immunoblot
of whole kidney protein samples from CRF and sham-operated
rats. (A) The immunoblot was reacted with affinity purified anti-
NHE3 and revealed a single ~87 kDa band. (B) Densitometric
analysis revealed a marked decrease in NHE3 expression in
the CRF-C, compared with CRF-V and sham-operated control
rats (Sham). *p<0.05 when CRF-V or CRF-C was compared
with sham-operated controls, 
� p<0.05 when CRF-C was com-
pared with CRF-V.
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Fig. 6. Decreased expression of TSC in CRF-C. Immunoblot of
whole kidney protein samples from CRF and sham-operated
rats. (A) The immunoblot was reacted with affinity purified anti-
TSC and revealed a broad band centered at ~164 kDa band.
(B) Densitometric analysis revealed a marked decrease in TSC
expression in CRF-C, compared with CRF-V and sham-oper-
ated controls. *p<0.05 when CRF-V or CRF-C was compared
with sham-operated controls, 
� p<0.05 when CRF-C was com-
pared with CRF-V. 
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DISCUSSION
In the present study, we demonstrated that 1) CRF rats
treated with candesartan were associated with decreased kid-
ney weight and increased BUN level compared with CRF
rats treated with vehicle; 2) CRF rats, both candesartan-treat-
ed and vehicle-treated, demonstrated decreased AQP2 levels
in remnant kidneys and this was likely to play a role in the
decreased urine concentration. The decreased AQP2 expres-
sion in CRF rats was not altered in response to candesartan
treatment; 3) Candesartan treatment was associated with
decreased NHE3 and TSC expression in CRF, which could
be due to the Ang II AT1 receptor blockade and/or decreased
aldosterone levels; and 4) BSC-1 expression was increased in
both CRF groups and the increased expression of BSC-1 was
more prominent in candesartan-treated CRF rats compared
with vehicle-treated CRF rats.
AT1 receptor blockade with candesartan treatment in CRF
rats was associated with decreased kidney weight and increas-
ed BUN levels, compared with CRF rats treated with vehicle
alone. This may indicate that AngII played a role in the pro-
cess of renal hypertrophy as a growth factor (16) and AT1
receptor blockade prevented or reduced renal hypertrophy
which is a common feature in remnant kidney. Consistent
with this, recent studies have shown that AngII acts as a
growth factor directly on the myocardium to cause ventric-
ular hypertrophy, and this response was prevented or reversed
by selective AT1 receptor antagonists (17). In addition, it is
of an interest to examine whether the hypertrophy of renal
tubular segments in remnant kidney is selectively responded
in response to AT1 receptor blockade. Morphometric studies
would be needed to elucidate this issue.
Urinary concentration and dilution depends on the pres-
ence of a discrete segmental distribution of transport proper-
ties along the renal tubule and urinary concentration depends
on 1) a hypertonic medullary interstitium, which is gener-
ated by active NaCl reabsorption as a consequence of counter-
current multiplication in water-impermeable nephron seg-
ments; 2) a high water permeability (constitutive or vasopre-
ssin-regulated) in other renal tubular segments for osmotic
equilibration, which chiefly depends on the expression of
aquaporins; and 3) flow rate of tubule fluid entering the me-
dullary collecting ducts (18, 19). Thus, defects in any of these
mechanisms would be predicted to be associated with urinary
concentrating defects.
The collecting duct represents the final site for the control
of water excretion into the urine (18, 20). Water permeability
of the collecting duct is tightly regulated, under the control
of the vasopressin, which causes a dramatic increase in col-
lecting duct water permeability, allowing reabsorption of
water from the tubular fluid down an osmotic gradient. In
the previous study (7), we found a marked reduction in the
expression of two collecting duct water channels AQP2 and
AQP3 in rats with CRF, indicating a defect in collecting duct
water reabsorption. This is consistent with previous functional
studies. First, in rats with CRF, micropuncture and micro-
catheterization studies have indicated that the impaired uri-
nary concentrating ability may, at least partly, be caused by
an impairment of vasopressin-stimulated water reabsorption
in the collecting duct (21). Secondly, patients with advanced
CRF have urine which remains hypotonic to plasma despite
the administration of supramaximal doses of vasopressin (22).
This vasopressin-resistant hyposthenuria specifically implies
abnormalities in collecting duct water reabsorption in CRF
patients. Thirdly, Fine et al. (23) observed that isolated and
perfused cortical collecting ducts dissected from remnant kid-
neys of severely uremic rabbits exhibited a defect in the res-
ponse to vasopressin. This was demonstrated both as a dec-
reased water flux (Jv) and decreased adenylate cyclase activi-
ty. Importantly, they also showed that the cAMP analogue
8-bromo-cAMP failed to induce a normal hydrosmotic res-
ponse in cortical collecting duct from remnant kidneys. As
an extension of these observations, Teitelbaum and McGuin-
ness (24) observed that RT-PCR of total RNA from the inner
medulla of CRF rat kidneys revealed virtual absence of V2
receptor mRNA. Thus, these studies all provide firm evidence
for the decreased of vasopressin-regulated water channel AQP2
expression and the significant defects in the collecting duct
of the kidneys from CRF.
In the present study, we further examine whether Ang II
AT1 receptor blocker candesartan treatment in rats with CRF,
where plasma vasopressin and AngII levels are elevated, could
alter the downregulation of renal AQP2 expression and dec-
reased urine concentration which were already seen in CRF
rats (7). In CRF, plasma vasopressin levels are already known
to be elevated. Moreover, in the present study rats with CRF
(both candesartan-treated and vehicle-treated) and sham-oper-
ated rats received a fixed amount of low sodium diet to increase
endogenous AngII and aldosterone levels, which was previ-
ously demonstrated in several studies (12-14) and to give
same amount of sodium intake. Interestingly, in a parallel
study, we found that treatment with the AT1 receptor blocker
candesartan in NaCl-restricted normal rats prevented the
increase of the expression of inner medullary AQP2 and phos-
phorylated-AQP2 (AQP2 phosphorylated in the PKA-phos-
phorylation consensus site Ser-256) and the increase of urine
concentration in response to the long-term dDAVP treatment
(25). This could be possible since there is cross-talk between
the signaling pathways of vasopressin and AngII (25-27). In
contrast, the present study examined on CRF rats did not
show any difference in total kidney AQP2 expression and
urine concentration between the NaCl-restricted CRF rats
treated with candesartan and NaCl-retricted CRF rats treat-
ed with vehicle alone. This is possible since CRF per se has
significant defects in collecting duct function in water reab-
sorption and vasopressin responsiveness as discussed previously
and thus this could not be like the case of normal rats.
The Na-K-2Cl cotransporter BSC-1, which is localized at254 E.-J. Kim, Y.-W. Jung, T.-H. Kwon
the apical plasma membrane domains of medullary and cor-
tical thick ascending limb segments, mediates the apical NaCl
transport in these water-impermeable segments (6, 28). This
pathway is critical for the generation of the hypertonic me-
dullary interstitium for concentrating urine. Consistent with
this, we have previously demonstrated that downregulation
of BSC-1 is associated with a marked reduction of urine con-
centration in several well characterized animal models, e.g.,
PTH-induced hypercalcemia (29) and low potassium diet-
induced hypokalemia (30). Moreover, it was demonstrated
that the expression of Na-K-2Cl cotransporter in the thick
ascending limb is increased in response to chronic oral saline
loading and dDAVP treatment in rats (31).
In the present study, we demonstrated an increase of BSC-
1 protein expression in CRF rats treated with vehicle com-
pared with sham-operated rats, and this was consistent with
our previous study demonstrating an increase of density per
nephron of BSC-1 in CRF rats (although the previous study
demonstrated unchanged protein expression of BSC-1 bet-
ween CRF and sham-operated rats (6)). The delivery of sodium
and water to the distal end of the proximal tubule of superficial
nephrons and to the bend of Henle’s loop of juxtamedullary
nephrons is known to be increased in remnant kidneys due to
an increase in the filtered load and a decrease in the fractional
reabsorption of sodium and water in the proximal tubule (21).
This condition may be similar to acute and chronic loading
with isotonic saline in normal rats. A large amount of evidence
indicates that isotonic saline loading is associated with an
elevation of SNGFR as well as a decrease in fractional proxi-
mal NaCl reabsorption. Furthermore, Landwehr et al. (32)
demonstrated that the increase in delivery to the loop of Henle
is associated with a marked increase in NaCl absorption by
the loop of Henle, presumably due in part to an increase in
TAL NaCl absorption. Consistent with this, Ecelbarger et al.
(31) demonstrated that chronic oral saline loading in rats mar-
kedly increased BSC-1 abundance in the TAL of rats. Thus,
we speculate that the increase in density of BSC-1 seen fol-
lowing 2 weeks after induction of 5/6 nephrectomy could,
at least in part, be a consequence of a prolonged increase in
the NaCl load delivered to the TAL due to both hyperfiltra-
tion and altered expression in the proximal sodium trans-
porters in remnant kidneys.
Moreover, candesartan treatment potentiated the upregu-
lation of BSC-1 protein expression in CRF rats, and this is
also compatible with the view that BSC-1 expression is reg-
ulated by the prolonged increase in the NaCl load delivered
to the TAL due to both hyperfiltration and altered expres-
sion in the proximal tubule sodium transporters in remnant
kidneys. Consistent with this, the protein expression of NHE3,
which is mainly localized at the apical membrane domains
of the proximal tubule and plays a role in the sodium reab-
sorption, was significantly decreased in CRF rats treated with
candesartan compared with CRF rats treated with vehicle
but the GFR between the two groups was not different. This
could induce an increased loading of NaCl and fluid into the
TAL, thereby increasing the BSC-1 expression. In contrast,
mice lacking NHE3 showed decreased expression of BSC-1
and sodium wasting (33), however they also had decreased
SNGFR in contrast to CRF (34). The observed decrease in
BSC-1 abundance in the NHE3 knockout mice is unexplained
based on current knowledge regarding the regulation of these
transporters and further investigation is needed to address this.
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